Cardiac Biomarker
Cardiac Biomarker Market by Type (Brain Natriuretic Peptide or NT-proBNP, Creatine Kinase, Ischemia Modified Albumin), Location of Testing (Laboratory Testing, Point of Care Testing), Application - Global Forecast 2024-2030
360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the cardiac biomarker market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[196 Pages Report] The Cardiac Biomarker Market size was estimated at USD 4.62 billion in 2023 and expected to reach USD 5.31 billion in 2024, at a CAGR 14.90% to reach USD 12.24 billion by 2030.

Cardiac biomarkers including troponin, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP), are critical for diagnosing and managing cardiovascular diseases (CVDs) by providing vital information on heart function through the detection of substances released during cardiac stress or injury. The market for these biomarkers involves their discovery, development, and commercialization, driven by factors such as the increasing prevalence of CVDs, technological advancements, an aging population, and investments in healthcare. Cardiac biomarkers are essential for diagnosing acute myocardial infarction (AMI), risk stratification, monitoring treatment effectiveness, and aiding in the development of new cardiovascular therapies. Hospitals, clinics, diagnostic laboratories, research institutions, and pharmaceutical and biotechnology companies are the primary end-users that benefit from these diagnostic tools. The market is ripe for growth due to opportunities in point-of-care testing (POCT), personalized medicine, expansion in emerging markets, and strategic collaborations. Challenges include stringent regulatory approval processes, high development costs, limited access to advanced diagnostics in certain regions, and standardization issues. Innovations focus on multiplex biomarker panels, integration with digital health, leveraging artificial intelligence (AI), and ongoing biomarker discovery.

Regional Insights
The cardiac biomarker market is thriving globally, driven by advanced healthcare infrastructure, substantial investments in research and development (R&D), and governmental initiatives in places such as the United States, the European Union (EU), and China. In the U.S., the FDA's stringent regulations ensure high standards, with companies including Abbott and Roche gaining rapid approvals for innovative diagnostics. China's policies, such as emphasizing diagnostics and healthcare innovation, support extensive market growth. Japan focuses on precision medicine, which is driven by technological advancements and significant healthcare research investment. Meanwhile, India's growing healthcare sector and government programs aiming to improve accessibility underscore its potential market growth. The market also sees robust demand in the Americas, driven by high cardiovascular disease rates and significant investments in Brazil and Mexico. Countries including South Africa are enhancing healthcare access and diagnostics in Africa. Recent industry events, such as new FDA approvals and the implementation of the EU's In Vitro Diagnostic Regulation (IVDR), are setting high standards. Companies are recommended to target emerging markets, invest in technology, foster collaborations, and embrace innovations in artificial intelligence (AI) and machine learning to seize significant market share. The U.S. FDA's stringent regulations for cardiac biomarkers emphasize accuracy, specificity, and clinical utility. Companies benefit from the Breakthrough Devices Program, aiding rapid approvals. Abbott and Roche have leveraged this to expedite high-sensitivity troponin tests and new diagnostics. The European Medicines Agency (EMA) and the In Vitro Diagnostic Regulation (IVDR) focus on compliance with quality and safety standards, although this results in longer approval timelines. Siemens Healthineers and BioMérieux have adjusted their strategies accordingly. China's National Medical Products Administration (NMPA) requires local clinical trials, which fosters domestic innovation.
Cardiac Biomarker Market
To learn more about this report, request a free PDF copy
Market Dynamics

The market dynamics represent an ever-changing landscape of the Cardiac Biomarker Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Growing incidence of cardiovascular diseases globally
    • Increasing awareness and need for early diagnosis of cardiovascular diseases
    • Surge in geriatric population and related heart diseases
  • Market Restraints
    • Technical issues pertinent to sample collection and storage
  • Market Opportunities
    • Emerging investment in research and development activities in cardiac biomarkers
    • Emerging demand for POC testing with cardiac biomarkers
  • Market Challenges
    • Concerns over regulatory and reimbursement systems
Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Cardiac Biomarker Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Cardiac Biomarker Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cardiac Biomarker Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Cardiac Biomarker Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Cardiac Biomarker Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Cardiac Biomarker Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Cardiac Biomarker Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Cardiac Biomarker Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Cardiac Biomarker Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Cardiac Biomarker Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

As a leading provider in the scientific community, we faced significant challenges in staying ahead of the curve regarding the awareness and need for early diagnosis of cardiovascular diseases. Before using the Cardiac Biomarker Market Research Report by 360iResearch, we struggled to gain actionable insights that could drive our strategy effectively. The comprehensive analysis provided in the report offered valuable insights into market trends, competitive landscape, and emerging opportunities. Specifically, we were able to identify key growth areas and tailor our approach to meet the market demands efficiently. The report's findings played a crucial role in enhancing our market awareness and expanding our reach. Overall, it has been a game-changer for our organization, significantly impacting our operations and strategy. We are extremely satisfied with the clarity and depth of information provided.
Thermo Fisher Scientific Inc.
FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Biomarker Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Biomarker Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Biomarker Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

We faced several challenges in understanding the surge in geriatric population and related heart diseases before utilizing the Cardiac Biomarker Market Research Report by 360iResearch. The valuable insights and actionable strategies provided by the report enabled us to tailor our product development and marketing efforts precisely to meet market demands. Specific examples include identifying key biomarkers that resonated with our target demographic, resulting in a significant increase in our market share. This report has been instrumental in driving our strategic decisions and overall growth. Our satisfaction with 360iResearch's comprehensive analysis and depth of information cannot be overstated.
Guangzhou Wondfo Biotech Co., Ltd.
Key Company Profiles

The report delves into recent significant developments in the Cardiac Biomarker Market, highlighting leading vendors and their innovative profiles. These include Thermo Fisher Scientific Inc., Guangzhou Wondfo Biotech Co., Ltd., DiaSorin S.p.A., bioMérieux SA, Beckman Coulter, Inc., Olympus Corporation, Becton, Dickinson and Company, Abbott Laboratories, Siemens Healthcare GmbH, Johnson & Johnson Services, Inc., PerkinElmer Inc., Quidel Corporation, F. Hoffmann-La Roche Ltd., Tosoh Corporation, and Randox Laboratories Ltd..

Cardiac Biomarker Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Cardiac Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Brain Natriuretic Peptide or NT-proBNP
    • Creatine Kinase
    • Ischemia Modified Albumin
    • Myoglobin
    • Troponins
  • Location of Testing
    • Laboratory Testing
    • Point of Care Testing
  • Application
    • Acute Coronary Syndrome
    • Atherosclerosis
    • Congestive Heart Failure
    • Myocardial Infarction

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

We faced significant challenges in identifying new investment opportunities in the rapidly evolving field of cardiac biomarkers. The Cardiac Biomarker Market Research Report from 360iResearch provided valuable insights and actionable strategies, enabling us to pinpoint emerging trends and make informed decisions. This report greatly enhanced our research and development activities, leading to improved innovation and competitive advantage. Our overall satisfaction with the report is exceedingly high, and it has positively impacted our operations.
DiaSorin S.p.A.
This research report offers invaluable insights into various crucial aspects of the Cardiac Biomarker Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Cardiac Biomarker Market, by Type
  7. Cardiac Biomarker Market, by Location of Testing
  8. Cardiac Biomarker Market, by Application
  9. Americas Cardiac Biomarker Market
  10. Asia-Pacific Cardiac Biomarker Market
  11. Europe, Middle East & Africa Cardiac Biomarker Market
  12. Competitive Landscape
  13. Competitive Portfolio
  14. List of Figures [Total: 22]
  15. List of Tables [Total: 290]
  16. List of Companies Mentioned [Total: 15]
Frequently Asked Questions
  1. How big is the Cardiac Biomarker Market?
    Ans. The Global Cardiac Biomarker Market size was estimated at USD 4.62 billion in 2023 and expected to reach USD 5.31 billion in 2024.
  2. What is the Cardiac Biomarker Market growth?
    Ans. The Global Cardiac Biomarker Market to grow USD 12.24 billion by 2030, at a CAGR of 14.90%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.